References of "Couturier, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detail68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies
Verger, Elise ULiege; Drion, Pierre ULiege; MEFFRE, Geneviève ULiege et al

in PLoS ONE (2016)

This work aims to develop, validate and optimize the radiolabeling of Starch-Based Microparticles (SBMP) by 188Re and 68Ga in the form of ready-to-use radiolabeling kits, the ultimate goal being to obtain ... [more ▼]

This work aims to develop, validate and optimize the radiolabeling of Starch-Based Microparticles (SBMP) by 188Re and 68Ga in the form of ready-to-use radiolabeling kits, the ultimate goal being to obtain a unique theranostic vector for the treatment of Hepatocellular Carcinoma. METHODS: Optimal labeling conditions and composition of freeze-dried kits were defined by monitoring the radiochemical purity while varying several parameters. In vitro stability studies were carried out, as well as an in vivo biodistribution as a preliminary approach with the intra-arterial injection of 68Ga radiolabeled SBMP into the hepatic artery of DENA-induced rats followed by PET/CT imaging. RESULTS: Kits were optimized for 188Re and 68Ga with high and stable radiochemical purity (>95% and >98% respectively). The in vivo preliminary study was successful with more than 95% of activity found in the liver and mostly in the tumorous part. CONCLUSION: SBMP are a promising theranostic agent for the Selective Internal Radiation Therapy of Hepatocellular carcinoma [less ▲]

Detailed reference viewed: 49 (8 ULiège)
Full Text
Peer Reviewed
See detail188Re and 68Ga radiolabeled Starch-Based Microparticles as potential theranostic radiopharmaceutical for Hepatocellular Carcinoma
Verger, Elise ULiege; Drion, Pierre ULiege; MEFFRE, Geneviève ULiege et al

in Journal of Nuclear Medicine (2016, May 01), 57(suppl. 2),

The SBMP as a unique vector is a promising theranostic agent for the SIRT of HCC.

Detailed reference viewed: 66 (11 ULiège)
Full Text
Peer Reviewed
See detailMicroparticules à base d’amidon radiomarquées au 188Re et 68Ga comme agent théranostique pour la radiothérapie interne sélective du carcinome hépatocellulaire
Verger, Elise ULiege; Drion, Pierre ULiege; MEFFRE, Geneviève ULiege et al

in Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique (2016, May), 40(3), 182

Les microparticules SBMP, en étant capable d'être radiomarquées rapidement, de manière reproductible, sous forme de kits prêt-à-l‘emploi, par du 188Re et du 68Ga, se révèlent être un outil théranostique ... [more ▼]

Les microparticules SBMP, en étant capable d'être radiomarquées rapidement, de manière reproductible, sous forme de kits prêt-à-l‘emploi, par du 188Re et du 68Ga, se révèlent être un outil théranostique prometteur pour le traitement du carcinome hépatocellulaire. [less ▲]

Detailed reference viewed: 60 (10 ULiège)
Full Text
See detailA theranostic tool for Hepatocellular carcinoma: the Starch-Based Microparticles
Verger, Elise ULiege; Cikankowitz, Annabelle; Bouvier, Antoine et al

Conference (2015)

Detailed reference viewed: 51 (6 ULiège)
Full Text
Peer Reviewed
See detailRadiolabelling of starch microparticles with Rhenium-188 for hepatocellular carcinoma’s therapy
Verger, Elise ULiege; Bouvier, Antoine; Benoit, Jean-Pierre et al

in European Journal of Nuclear Medicine and Molecular Imaging (2014, October), 41(Supplement 2), 443-444

Detailed reference viewed: 23 (5 ULiège)
Full Text
See detailRadiomarquage au 188Re des microparticules à base d’amidon pour la thérapie du carcinome hépatocellulaire
Verger, Elise ULiege; Bouvier, Antoine; Benoit, Jean-Pierre et al

Poster (2014)

Detailed reference viewed: 31 (4 ULiège)
Full Text
See detailStarch based microparticles radiolabelling with 99mTc and 188Re for diagnostic and therapy of Hepatocellular carcinoma
Verger, Elise ULiege; Cikankowitz, Annabelle; Bouvier, Antoine et al

Conference (2014)

Detailed reference viewed: 26 (2 ULiège)
Full Text
See detailDevelopment of a new selective internal radiation therapy and diagnostic tool for hepatocellular carcinoma: the starch-based microspheres
Verger, Elise ULiege; Cikankowitz, Annabelle; Bouvier, Antoine et al

Poster (2014)

Detailed reference viewed: 21 (4 ULiège)
Full Text
See detailNanomédecines et micromédecines pour la radiothérapie vectorisée appliquée au traitement du Carcinome Hepato-Cellulaire
Verger, Elise ULiege; Lacoeuille, Franck; Couturier, Olivier et al

Poster (2013)

Detailed reference viewed: 26 (6 ULiège)
Full Text
See detailNanomedicines and micromedicines for vectorised radiotherapy of Hepatocellular Carcinoma
Verger, Elise ULiege; Belloche, Camille; Cikankowitz, Annabelle et al

Poster (2013)

Detailed reference viewed: 37 (4 ULiège)
Full Text
Peer Reviewed
See detailSequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer.
Couturier, Olivier; Jerusalem, Guy ULiege; N'Guyen, Jean-Michel et al

in Clinical Cancer Research (2006), 12(21), 6437-43

PURPOSE: To evaluate the clinical value of positron emission tomography (PET) for monitoring chemotherapy in metastatic breast cancer. EXPERIMENTAL DESIGN: Twenty patients with hormonorefractory or ... [more ▼]

PURPOSE: To evaluate the clinical value of positron emission tomography (PET) for monitoring chemotherapy in metastatic breast cancer. EXPERIMENTAL DESIGN: Twenty patients with hormonorefractory or hormonoreceptor-negative multimetastatic breast cancer were prospectively included. PET studies were done at baseline, at day 21 after the first cycle and at day 21 after the third cycle of chemotherapy. Metabolic response was defined based on visual and various modes of standardized uptake value (SUV) analysis of sequential PET studies. RESULTS: After one cycle, PET indicated a partial response in 12 patients, stable disease in 7 patients, and progressive disease in 1 patient, according to the visual analysis. After three cycles, PET showed a complete response in 5 patients, partial response in 11 patients, stable disease in 3 patients, and progressive disease in 1 patient. Seventy-five percent of the patients showing a metabolic response on visual analysis effectively responded to the treatment. The average SUV decreased on both the second and the third PET study, but only changes measured after three cycles of chemotherapy predicted the clinical response to chemotherapy and the overall survival. All methods for calculating the SUV (normalized for body weight, body surface area, or lean body mass) provided similar results. CONCLUSION: Semiquantitative analysis of [18F]fluorodeoxyglucose-PET studies done after three cycles of chemotherapy is useful for monitoring the response to chemotherapy in metastatic breast cancer. [less ▲]

Detailed reference viewed: 33 (9 ULiège)
Full Text
Peer Reviewed
See detailIs 3 '-deoxy-3 '-[F-18] fluorothymidine ([F-18]-FLT) the next tracer for routine clinical PET after R [F-18]-FDG?
Couturier, Olivier; Léost, Françoise; Campone, Mario et al

in Bulletin du Cancer (2005), 92(9), 789-798

Positron emission tomography (PET) with {F-18}-FDG is nowfirmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its ... [more ▼]

Positron emission tomography (PET) with {F-18}-FDG is nowfirmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its uptake mechanism for tumors, or the low avidity of some cancer types such as prostate. Alternative tracers are thus being developed, in order to fill up this void. Proliferation as a biological target is particularly attractive in cancer imaging. From that perspective, fluorothymidine ({F-18}-FLT or FLT) has generated a strong interest among the scientific community, especially since the radiosynthesis process has been improved and simplified, thus making possible to envision a routine use for the tracer. This article aims at summarizing the status of the current scientific data regarding FLT The uptake mechanism of FLT is well known, relying on the thymidine kinase 1 (TK1) enzymatic activity, and thus on DNA synthesis, Preclinical studies have shown a clear relationship between tracer accumulation and level of tumor proliferation, even though DNA salvage pathwayss intervene in the process and may complicate the interpretation of the results. Several clinical studies suggest a good specificity for tumor, albeit with a lower sensitivity than with FDG. In all likelihood however, the future of FLT lies in the evaluation of antitumor response and possibly the pretherapeutic prognostic characterization, rather than in the diagnosis and staging of malignancies. Although the scientific data regarding this issue remain limited, initial results are encouraging. Further significant work remains to he done in order to fully assess the clinical performances of the tracer, on the one hand, and to determine its place relative to FDG and other emerging tracers, on the other hand. Until these studies are completed, FLT should he considered as a promising tracer, hut remaining at an experimental stage of its development. [less ▲]

Detailed reference viewed: 44 (1 ULiège)
Full Text
Peer Reviewed
See detailLa 3'-deoxy-3'-[18F] fluorothymidine ([18F]-FLT) est-elle le prochain traceur utilise en routine pour la TEP apres le [18F]-FDG?
Couturier, Olivier; Leost, Francoise; Campone, Mario et al

in Bulletin du Cancer (2005), 92(9), 789-98

Positron emission tomography (PET) with [18F]-FDG is now firmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its ... [more ▼]

Positron emission tomography (PET) with [18F]-FDG is now firmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its uptake mechanism for tumors, or the low avidity of some cancer types such as prostate. Alternative tracers are thus being developed, in order to fill up this void. Proliferation as a biological target is particularly attractive in cancer imaging. From that perspective, fluorothymidine ([18F]-FLT or FLT) has generated a strong interest among the scientific community, especially since the radiosynthesis process has been improved and simplified, thus making possible to envision a routine use for the tracer. This article aims at summarizing the status of the current scientific data regarding FLT. The uptake mechanism of FLT is well known, relying on the thymidine kinase 1 (TK1) enzymatic activity, and thus on DNA synthesis. Preclinical studies have shown a clear relationship between tracer accumulation and level of tumor proliferation, even though DNA salvage pathwayss intervene in the process and may complicate the interpretation of the results. Several clinical studies suggest a good specificity for tumor, albeit with a lower sensitivity than with FDG. In all likelihood however, the future of FLT lies in the evaluation of antitumor response and possibly the pretherapeutic prognostic characterization, rather than in the diagnosis and staging of malignancies. Although the scientific data regarding this issue remain limited, initial results are encouraging. Further significant work remains to be done in order to fully assess the clinical performances of the tracer, on the one hand, and to determine its place relative to FDG and other emerging tracers, on the other hand. Until these studies are completed, FLT should be considered as a promising tracer, but remaining at an experimental stage of its development. [less ▲]

Detailed reference viewed: 117 (3 ULiège)
Full Text
Peer Reviewed
See detailFluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography
Couturier, Olivier; Chatal, Jean-François; Hustinx, Roland ULiege

in Bulletin du Cancer (2004), 91(9), 695-703

F-18-FDG is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine 18 is considered as the ideal radioisotope for PET, thanks to a low positron energy ... [more ▼]

F-18-FDG is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine 18 is considered as the ideal radioisotope for PET, thanks to a low positron energy, which not only limits the dose rate to the patients but also provides high-resolution images. Furthermore, the 110 min. physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site, and imaging protocols that could span hours, which permits dynamic studies and assessing metabolic processes that may be fairly slow Recently, synthesis of fluorinated tracers from prosthetic group precursors, which allows easier radiolabeling of biomolecules, has given a boost to the development of numerous fluorinated tracers, Given the wide availability of fluorine 18, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated analogs of nucleosides and fluorinated radiotracers of gene expression recently developed and under investigation. [less ▲]

Detailed reference viewed: 21 (3 ULiège)
Full Text
Peer Reviewed
See detailFluorinated tracers for imaging cancer with positron emission tomography
Couturier, Olivier; Luxen, André ULiege; Chatal, Jean-François et al

in European Journal of Nuclear Medicine and Molecular Imaging (2004), 31(8), 1182-1206

2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET ... [more ▼]

2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes "generalist" tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of "specific" tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism. [less ▲]

Detailed reference viewed: 66 (2 ULiège)
Full Text
Peer Reviewed
See detailTraceurs fluorés de la prolifération des cancers en tomographie par émission de positons
Couturier, Olivier; Bodet-Milin, C.; Cherel, M. et al

in Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique (2004), 28(8), 371-376

Le 18F-fluorodeoxyglucose (FDG) est actuellement le seul traceur fluoré utilisé en routine en tomographie par émission de positons (TEP). Le fluor 18 peut être considéré comme le radioisotope TEP idéal ... [more ▼]

Le 18F-fluorodeoxyglucose (FDG) est actuellement le seul traceur fluoré utilisé en routine en tomographie par émission de positons (TEP). Le fluor 18 peut être considéré comme le radioisotope TEP idéal avec : 1) une émission positonique de faible énergie (0,64 MeV), limitant l'irradiation reçue par le patient ainsi que le parcours du positon dans les tissus (2,3 mm), avec comme conséquence directe, une haute résolution des images TEP; 2) une période de 110 minutes permettant une radiosynthèse avec un bon rendement, un transport depuis l'établissement de radiopharmacie vers des services de médecine nucléaire distants, et des protocoles d'imagerie pouvant s'étendre sur quelques heures, ce qui facilite les études dynamiques et de processus métaboliques relativement lents. Récemment, la radiosynthèse fluorée à partir de groupes prothétiques précurseurs, qui permet le marquage de molécules bioactives dans de bonnes conditions, a donné un nouvel élan au développement de nombreux traceurs fluorés. En raison de la disponibilité du fluor, ils pourraient occuper dans un avenir proche une place importante en routine. Cet article et une revue de la littérature concernant les traceurs fluorés récemment développés et/ou en cours d'investigation, susceptibles d'être employés pour évaluer la prolifération tumorale. [less ▲]

Detailed reference viewed: 61 (8 ULiège)
Full Text
See detailNew strategies and new impact of cancer imaging
Couturier, Olivier; Hustinx, Roland ULiege; Chatal, Jean-François

in SERVIER, Jacques (Ed.) Cancer : recent evidence, innovative strategies, future promises (2004)

Detailed reference viewed: 16 (0 ULiège)